Journal
EXPERT REVIEW OF PROTEOMICS
Volume 13, Issue 7, Pages 673-684Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14789450.2016.1205950
Keywords
Biomarker; clinic; disease; MRM; MS; PRM; protein; proteomics; quantification; translation
Categories
Funding
- Health Research Board (HRB) [HRA_POR/2011/125, POR/2015/1284]
- St Luke's Institute of Cancer Research
- European Commission under the EU FP7 project 'MIAMI'
- Science Foundation Ireland
- Programme for Research in Third level Institutions
- Health Research Board (HRB) [HRA-POR-2011-125] Funding Source: Health Research Board (HRB)
Ask authors/readers for more resources
Introduction: Aided by the advent of advanced mass spectrometry (MS)-based technologies and methodologies, quantitative proteomics has emerged as a viable technique to capture meaningful data for candidate biomarker evaluation. To aid clinical translation, these methods generally utilize a bottom-up strategy with isotopically labeled standards and a targeted form of MS measurement.Areas covered: This article reviews the status, challenges, requirements, and potential of translating current, MS-based methods to the clinical laboratory. The described methods are discussed and contrasted within a fit-for-purpose approach, while different resources for quality control, quantitative analysis, and data interpretation are additionally provided.Expert commentary: Although great strides have been made over the past five years in developing reliable quantitative assays for plasma protein biomarkers, it is crucial for investigators to have an understanding of the clinical validation process, a major roadblock in translational research. Continued progress in method design and validation of protein assays is necessary to ultimately achieve widespread adoption and regulatory approval.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available